To learn more about bladder cancer and other urothelial cancers that affect the urinary system, Memorial Sloan Kettering has created a large database of genetic and clinical information, called a “research registry” for bladder cancer.
Information gathered for the Genotype-Phenotype Urothelial Cancer Study could lead to advances both in treating bladder cancer and in identifying who is at high risk for the disease. We may be able to identify more-targeted anticancer drugs, for example, or clarify who is at high risk for developing the cancer. Findings will also help us to identify:
- risk factors that increase the likelihood that someone will develop bladder cancer
- genetic markers in saliva that might be associated with a particular cancer
- genes that may predict a person’s risk for bladder cancer
- genes that may predict a person’s response to bladder cancer treatment
What are the benefits of joining?
For people already diagnosed with bladder cancer, the research registry could help in developing ways to predict response to certain treatments based on genetic makeup. The hope is also that findings will someday help identify who is at high risk for developing the disease, so that screening can be started early.
We invite family members of patients with urothelial cancers, patients age 18 and older, and individuals who have come for a consultation but are cancer-free to participate in this registry.
What is involved if I join?
In addition to questions about your family medical history and past or current smoking or alcohol consumption, you will be asked to provide small samples of saliva or blood for genetic testing.
For more information and to inquire about eligibility, please contact Dr. Dean Bajorin at 646-422-4333.